e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is
MIF -173G/C
polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility?
M. Gomes, A. Coelho, A. Araújo, R. Catarino, R. Medeiros (Porto, Portugal)
Source:
Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Session:
Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Session type:
Thematic Poster Session
Number:
2355
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Gomes, A. Coelho, A. Araújo, R. Catarino, R. Medeiros (Porto, Portugal). Is
MIF -173G/C
polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility?. Eur Respir J 2010; 36: Suppl. 54, 2355
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Arg72Pro
P53
gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
A non-small cell lung cancer modelling by endogenous κ-ras manipulation
Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection
Year: 2005
Association of Pre-miR-rs2910164 polymorphism with non-small cell lung cancer in an Iranian population
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept